Language
中文
Efficient execution capabilities and strengths
Launch >10 clinical PoC studies within 2years
R&D
Strong technology platforms and cellular immunotherapies
Operation
Seasoned team with rich experience to conduct PD/AD, manufacturing and quality specification, regulation, and clinical development
Clinical source
Strong alliance with top tier hospitals (18 Class 3A hospitals, total 50,000 beds)
Manufacturing facility
Global standards of cell gene therapy manufacturing(compliance with EMA and FDA)
Funding
Sophisticated investors, continuous and long-term investment
Policy
Continuous support to fuel biotech innovations
Please contact us
T : +86-21-64031375
M : Linc.he@gracellbio.com